New Cancer Pill Given Standing Ovation at Oncology Conference
Summary
A new pill called daraxonrasib, designed to treat pancreatic cancer, showed promising results by nearly doubling patient survival in a major late-stage trial. Doctors at a large cancer conference gave the drug a standing ovation after hearing about its success in blocking a protein that helps cancer grow.Key Facts
- Daraxonrasib targets a mutated protein called KRAS, which causes tumor growth in over 90% of pancreatic cancer cases.
- Pancreatic cancer kills about 50,000 Americans yearly and has a very low five-year survival rate for advanced cases (3%).
- The treatment lowers the risk of death by 60% compared to standard chemotherapy.
- In the trial, patients using daraxonrasib lived an average of 13.2 months versus 6.6 months with chemotherapy.
- Side effects led to stopping treatment in only 1.2% of patients taking daraxonrasib, much fewer than with chemotherapy (11.2%).
- The results were presented at the 2026 ASCO Annual Meeting in Chicago and published in a leading medical journal.
- Daraxonrasib is the first drug to effectively inhibit the KRAS protein across multiple genetic variants.
- The drug was developed by Revolution Medicines, which funded the clinical study.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.